Regulatory submissions for pharmaceutical products must demonstrate that the evidence presented is traceable to the underlying data and analyses that generated it. This traceability requirement exists because regulatory reviewers need to verify that summary claims accurately represent study results, that data has been appropriately collected and analysed, and that the benefit-risk assessment is grounded in the totality of available evidence. Meeting this requirement in a well-documented, machine-verifiable way is one of the most resource-intensive aspects of drug development — and one of the areas where structured knowledge infrastructure offers the most consequential efficiency gains.
The Traceability Gap in Current Practice
In most pharmaceutical organisations, the evidence chain from raw clinical data to regulatory submission narrative is documented across a combination of statistical analysis plans, study reports, database lock documentation, and submission narratives. These documents exist, but the connections between them are maintained in narrative form — text cross-references from one document to another — rather than as machine-readable links. Verifying a specific claim in a submission narrative requires locating the relevant study report, finding the relevant table or figure, tracing back to the statistical analysis plan, and confirming that the analysis was pre-specified. This manual tracing is time-consuming and error-prone, and the burden falls on both the submitting organisation and the regulatory reviewer.
When a reviewer requests clarification on a specific claim, the organisation must reconstruct the traceability chain manually — an exercise that can take weeks if the documentation is spread across a complex development programme spanning multiple studies, multiple data cuts, and multiple vendors. The effort is duplicated for each query, because the traceability infrastructure that would make the first query instant does not exist.
Knowledge Graph Traceability Infrastructure
A structured knowledge layer that represents the evidence chain as a machine-readable graph transforms this process. Each claim in the submission is represented as an assertion in the knowledge graph, linked to the analysis that generated it, the dataset that was analysed, the protocol that specified the analysis, and the raw data from which the dataset was derived. Each link is an explicit, navigable relationship in the graph. When a reviewer queries a specific claim, the knowledge graph returns not just the claim but the complete provenance chain — this efficacy finding, from this analysis, specified in this SAP, executed on this locked dataset, derived from these case report forms, completed at these sites. The reviewer navigates this chain interactively rather than searching across multiple documents.
Protocol Deviation Tracking and Impact Assessment
Protocol deviations present a particular traceability challenge in regulatory submissions. When a deviation occurs, its potential impact on analysis results and submission claims must be assessed and documented. In a structured knowledge system, protocol deviations are represented as explicit events with links to the affected patients, affected data points, and affected analyses. Impact assessment becomes a graph query — identifying which submission claims are supported by analyses that include data from affected patients — rather than a manual review of all study documentation. The completeness of the impact assessment is verifiable because the knowledge graph contains a comprehensive representation of the evidence chain.
Cross-Submission Consistency
Regulatory traceability infrastructure also enables consistency checking across submissions. A company filing in multiple jurisdictions, or updating a product label based on new post-marketing data, needs to ensure that claims in the updated submission are consistent with claims in prior submissions and with the totality of available evidence. Knowledge graph-based traceability makes this consistency checking tractable: a query can identify all claims made in prior submissions referencing a specific drug-indication combination, and compare them against claims proposed for the new submission, flagging discrepancies for review before they reach the regulatory agency.
Positioning for Machine-Readable Submissions
Regulatory agencies in multiple jurisdictions have signalled growing interest in structured, machine-readable submissions that enable more efficient review. The CDISC standards and emerging agency data submission guidance both point toward a future where evidence chains are machine-navigable rather than purely narrative. Organisations that build knowledge graph-based traceability infrastructure aligned with these emerging expectations position themselves for faster review cycles, more productive regulatory interactions, and a reduced burden of post-submission query response — an investment that pays dividends at each submission and compounds across the full regulatory lifecycle of the product.
